Olvi-Vec with platinum plus etoposide for late-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1/2 interventional trial gives an oncolytic virus product, Olvi-Vec, together with platinum (cisplatin or carboplatin) and etoposide to patients with extensive-stage small cell lung cancer who have progressed after prior platinum-based therapy and other guideline-recommended treatments. The study enrolls adults with at least one measurable lesion, ECOG 0–1, and adequate bone marrow, liver, and kidney function. GLP preclinical safety, pharmacology, and toxicology studies for Olvi-Vec have been completed and clinical testing of the agent in other tumor types is ongoing. The trial is designed to collect safety, tolerability, and initial activity data for the combination in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able to understand and voluntarily sign an informed consent form.
* Age ≥ 18 years old, gender not limited.
* Small cell lung cancer confirmed by organization or cytology.
* After receiving platinum based chemotherapy regimens and/or immunotherapy, platinum based chemotherapy regimens and/or anlotinib, and other recommended treatments according to guidelines, disease progression or recurrence has occurred.
* There should be at least one measurable target lesion during the baseline period, according to RECIST 1.1 (if a lesion that has received radiation therapy has obvious evidence of disease progression after radiation therapy, it can be used as a target lesion).
* ECOG physical condition score 0 or 1.
* Have sufficient bone marrow, liver and kidney organ function-

Exclusion Criteria:

* Compound small cell lung cancer and transformed small cell lung cancer.
* Patients with brain metastases and neurological symptoms; Note: Subjects with previous imaging evidence of brain metastases who have undergone local treatment (such as radiotherapy or surgery) for intracranial metastases and have stable lesions for more than 28 days without symptoms can be enrolled.
* Other primary malignant tumors other than small cell lung cancer (excluding non melanoma skin cancer, breast cancer in situ, cervical cancer in situ, and superficial bladder cancer, or other cancers that have been effectively controlled in the past three years and have no evidence of disease recurrence) were previously or currently combined.
* Clinically significant cardiovascular diseases At the beginning of the study treatment, the toxicity associated with previous anti-tumor treatments did not recover to ≤ CTCAE grade 1, except for hair loss and peripheral neurotoxicity of CTCAE grade 2.
* Known HIV infection (HIV antibody positive), active hepatitis B and C patients.
* Receive chemotherapy, targeted therapy, radiotherapy, and biological therapy, with less than 4 weeks since the first administration in this study; Or have received local radiotherapy within 2 weeks.
* Having undergone major surgery or significant traumatic injury within 28 days prior to the first administration of the investigational drug -

Where it's running

• Zhejiang Provincial People's Hospital
  Hangzhou, China Recruiting
• Shanghai chest hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Hannah Chen
• Email: hannah.chen@newsoara.com
• Phone: +8613801955339

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YL201 plus serplulimab vs the usual chemo combo as first treatment for extensive-stage small cell lung cancer

  This trial tests whether adding YL201 to serplulimab can improve outcomes compared with standard carboplatin and etoposide plus serplulimab in adults with treatment-naïve extensive-stage SCLC.

  Recruiting at 2 sites Phase 3 MediLink Therapeutics (Suzhou) Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07739758

• Using a new PFD3 PET tracer to find and stage small cell lung cancer

  This test will try a new PET tracer called PFD3 in adults with small cell lung cancer to see if it detects tumors and stages disease more accurately than standard FDG PET/CT.

  Recruiting Phase 1/2 Peking University First Hospital · Beijing, Beijing Municipality · NCT07508852

• Adaptive Phase 1/2 testing dual-target CAR‑NK cells for relapsed or refractory small cell lung cancer

  This trial tests off-the-shelf dual-target CAR‑NK cell therapy in adults with relapsed or refractory extensive-stage small cell lung cancer to see if it is safe and can shrink tumors.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07480213

• Maintenance treatment with [225Ac]Ac-DOTATATE plus tislelizumab for extensive‑stage small cell lung cancer with somatostatin receptor–positive tumors

  This trial will try to see if adding a targeted radioligand ([225Ac]Ac‑DOTATATE) to the immunotherapy drug tislelizumab as maintenance helps people with extensive‑stage small cell lung cancer whose tumors are somatostatin receptor positive after first‑line treatment.

  Recruiting Phase 1 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT07413042

• Safety and tolerability of NEUK203-13 CAR-NK cells for DLL3 in advanced neuroendocrine tumors

  This early phase trial tests NEUK203-13, an off-the-shelf CAR-NK cell therapy, in adults with advanced SCLC or other neuroendocrine tumors to see if it is safe and if it shows any anti-tumor activity.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07366658

• Bemotuzumab with chemotherapy and anlotinib, then targeted radiotherapy for extensive-stage small cell lung cancer

  This phase 2 study tests whether a combination of bemotuzumab, chemotherapy, and anlotinib, followed by continued bemotuzumab and anlotinib with thoracic radiotherapy, can help untreated extensive-stage small cell lung cancer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07358676

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.